Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2014: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2013: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2012: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
Outline of Final Research Achievements |
Purpose of this study is that development of novel therapies for ischemic heart disease or cancer through manipulating vascular formation using advanced pluripotent stem cell research. We demonstrated that kappa-opioid receptor suppressed tumor angiogenesis through inhibiting expression of type II vascular endothelial growth factor receptor. In addition, we reported a novel function of angiopoietin-1 in coronary vein formation as a collaboration with Department of cardiovascular medicine, University of Tokyo.
|